Dec 8, 2008 - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that it has signed an exclusive agreement with PharmaSwiss SA for the marketing of Elestrin (estradiol gel) in Israel. Elestrin is indicated in the U.S. for the treatment of moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause. PharmaSwiss is responsible for regulatory and marketing activities in Israel. Financial terms of the agreement were not disclosed.
The details can be read here.
No comments:
Post a Comment